123 related articles for article (PubMed ID: 33517336)
21. Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
Carlsson S; Benfante N; Alvim R; Sjoberg DD; Vickers A; Reuter VE; Fine SW; Vargas HA; Wiseman M; Mamoor M; Ehdaie B; Laudone V; Scardino P; Eastham J; Touijer K
J Urol; 2020 Jun; 203(6):1117-1121. PubMed ID: 31909690
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
[TBL] [Abstract][Full Text] [Related]
23. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.
Gielchinsky I; Chang J; Cusick T; Delprado W; Nguyen Q; Yuen C; Savdie R; Böhm M; Haynes AM; Scheltema MJ; Stricker PD
BJU Int; 2018 Nov; 122 Suppl 5():35-41. PubMed ID: 30303599
[TBL] [Abstract][Full Text] [Related]
25. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
26. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
Reinhold T; Dornquast C; Börgermann C; Weißbach L
Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study.
Abdel-Rahman O
Clin Transl Oncol; 2019 Dec; 21(12):1673-1679. PubMed ID: 30929179
[TBL] [Abstract][Full Text] [Related]
28. [Patterns of care of patients with localized prostate cancer in Germany: a health care study with focus on active surveillance].
Chun FK; Becker A; Kluth LA; Seiler D; Schnell D; Fisch M; Graefen M; Weissbach L
Urologe A; 2015 Jan; 54(1):6-13. PubMed ID: 25391440
[TBL] [Abstract][Full Text] [Related]
29. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
30. Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate.
Nunez R; Hurd KJ; Noble BN; Castle EP; Andrews PE; Humphreys MR
Int J Urol; 2011 Jul; 18(7):543-7. PubMed ID: 21592233
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Kellokumpu-Lehtinen PL; Hjälm-Eriksson M; Thellenberg-Karlsson C; Åström L; Franzen L; Fransson AS; Leskinen MJ; Zeke M; Huttunen T; Ginman C;
Eur Urol; 2019 Dec; 76(6):823-830. PubMed ID: 31443961
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Ahlgren GM; Flodgren P; Tammela TLJ; Kellokumpu-Lehtinen P; Borre M; Angelsen A; Iversen JR; Sverrisdottir A; Jonsson E; Sengelov L;
Eur Urol; 2018 Jun; 73(6):870-876. PubMed ID: 29395502
[TBL] [Abstract][Full Text] [Related]
33. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer.
Thomsen FB; Røder MA; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Brasso K
Clin Genitourin Cancer; 2019 Aug; 17(4):e814-e821. PubMed ID: 31196798
[TBL] [Abstract][Full Text] [Related]
34. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
35. Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study.
Thomsen FB; Jakobsen H; Langkilde NC; Borre M; Jakobsen EB; Frey A; Lund L; Lunden D; Dahl C; Helgstrand JT; Brasso K
J Urol; 2019 Mar; 201(3):520-527. PubMed ID: 30240689
[TBL] [Abstract][Full Text] [Related]
36. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
[TBL] [Abstract][Full Text] [Related]
37. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.
Bandini M; Nazzani S; Marchioni M; Preisser F; Tian Z; Moschini M; Abdollah F; Suardi N; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2019 Feb; 17(1):72-78.e4. PubMed ID: 30342845
[TBL] [Abstract][Full Text] [Related]
38. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
[TBL] [Abstract][Full Text] [Related]
39. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.
Salari K; Kuppermann D; Preston MA; Dahl DM; Barrisford GW; Efstathiou JA; Blute ML; Vesprini D; Loblaw A; Zietman AL; Klotz L; Feldman AS
J Urol; 2019 Apr; 201(4):721-727. PubMed ID: 30664083
[TBL] [Abstract][Full Text] [Related]
40. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
